Pathologic inclusions define α-synucleinopathies that include Parkinson's disease (PD). The
most common genetic cause of PD is the G2019S LRRK2 mutation that upregulates LRRK2 …

Lowering of prion protein (PrP) expression in the brain is a genetically validated therapeutic
hypothesis in prion disease. We recently showed that antisense oligonucleotide (ASO)-…

The blood barriers of the nervous system protect neural environments but can hinder
therapeutic accessibility. The blood-brain barrier (BBB) is well characterized, consisting of …

Antisense oligonucleotides (ASOs) dosed into cerebrospinal fluid (CSF) distribute broadly
throughout the central nervous system (CNS). By modulating RNA, they hold the promise of …

Mutations in PLP1, the gene that encodes proteolipid protein (PLP), result in failure of
myelination and neurological dysfunction in the X-chromosome-linked leukodystrophy Pelizaeus–…

Autosomal dominant pathogenic mutations in Leucine-rich repeat kinase 2 (LRRK2) cause
Parkinson’s disease (PD). The most common mutation, G2019S-LRRK2, increases the …

Prion protein (PrP) concentration controls the kinetics of prion replication and is a genetically
and pharmacologically validated therapeutic target for prion disease. In order to evaluate …

There is an urgent need for better treatments for chronic pain, which affects more than 1 billion
people worldwide. Antisense oligonucleotides (ASOs) have proven successful in treating …

The magnetic anisotropy of YCo4B determined by the singular point detection (SPD) method
and magnetization measurements over 3 large range of temperature is reported. The …

Antisense oligonucleotides (ASOs) designed to lower prion protein (PrP) expression in the
brain through RNase H1-mediated degradation of PrP RNA are in development as prion …